All-cause mortality and liver-related outcomes following successful antiviral treatment for chronic hepatitis C. (Q33413353)

26 July 2017

title

All-cause mortality and liver-related outcomes following successful antiviral treatment for chronic hepatitis C. (English)

1 reference

26 July 2017

1 reference

Eric Dieperink

1

1 reference

26 July 2017

Christine Pocha

2

1 reference

26 July 2017

Paul Thuras

3

1 reference

26 July 2017

Astrid Knott

4

1 reference

26 July 2017

Samuel Colton

5

1 reference

26 July 2017

Samuel B Ho

6

1 reference

26 July 2017

publication date

15 February 2014

1 reference

Digestive Diseases and Sciences

26 July 2017

published in

1 reference

26 July 2017

volume

59

1 reference

26 July 2017

issue

4

1 reference

26 July 2017

page(s)

872-880

1 reference

Hepatitis C virus infection: the new global epidemic

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3050-5

The epidemiology of hepatitis C infection in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3050-5

The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3050-5

Telaprevir for previously untreated chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3050-5

Boceprevir for untreated chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3050-5

Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3050-5

Sofosbuvir for previously untreated chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3050-5

A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3050-5

Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3050-5

Peginterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: outcomes and factors predicting response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3050-5

Outcome of sustained virological responders with histologically advanced chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3050-5

Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3050-5

Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3050-5

Effects of interferon treatment on development and progression of hepatocellular carcinoma in patients with chronic virus infection: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3050-5

A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3050-5

Management of chronic hepatitis C in veterans: the potential of integrated care models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3050-5

Integrated psychiatric/medical care in a chronic hepatitis C clinic: effect on antiviral treatment evaluation and outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3050-5

An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3050-5

Long-term outcome of chronic hepatitis C after sustained virological response to interferon-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3050-5

Manifestations of chronic hepatitis C virus infection beyond the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3050-5

Abnormalities of lipid metabolism in hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3050-5

Peripheral platelet count correlates with liver atrophy and predicts long-term mortality on the liver transplant waiting list

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3050-5

A randomized controlled trial of an integrated care intervention to increase eligibility for chronic hepatitis C treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3050-5

Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3050-5

Integrating care for patients with infectious, psychiatric, and substance use disorders: concepts and approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3050-5

Review article: the modern management of hepatic encephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3050-5

Minimal hepatic encephalopathy is associated with motor vehicle crashes: the reality beyond the driving test

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3050-5

A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3050-5

Addressing tri-morbidity (hepatitis C, psychiatric disorders, and substance use): the importance of routine mental health screening as a component of a comanagement model of care.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3050-5

Natural history of hepatitis C

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24532254

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S10620-014-3050-5

1 reference

Dimensions Publication ID

26 July 2017

1027482570

0 references

1 reference